Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

Carboplatin 4Pemetrexed 3pembrolizumab 2patritumab 2osimertinib 2Sunitinib 2Standard of Care 2Paclitaxel 2Irinotecan 2Cisplatin 2Ascorbic Acid 2valrubicin 1pralsetinib 1palbociclib 1napabucasin 1linifanib 1genexol-PM 1dostarlimab 1alectinib 1Watchful Waiting 1Sorafenib 1Ramucirumab 1Patient Reported Outcome Measures 1Mitomycin 1KRN-330 1Interleukin-2 1Indocyanine Green 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Site × BAY 86-7548 × Clear all
NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Lantheus Biosciences Ltd.

Phase 1/2 Terminated
30 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡